Sun Pharmaceutical Industries Ltd. (Sun Pharma) is an international specialty pharmaceutical company. The Company’s product portfolio consists of four categories of products: India branded generics, US generics, international branded generics and active pharmaceutical ingredients (API). The products of the Company are prescribed in therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. The products manufactured by the Company include Supatret, Winolap, Donamem, Exmasin, Lenzest, Octride Depot 10, Carcidox, Tyrogef, Cernos depot, Milnorm, Levipil, Exzilor and Macorate. The Company’s subsidiaries include Sun Pharma Global Inc. BVI., Sun Pharma Global-FZE, Sun Pharmaceutical (Bangladesh) Ltd., Sun Pharmaceutical Peru S.A.C. and Sun Farmaceutica Ltda-Brazil. In November 2008, the Company, along with its subsidiaries, completed the acquisition of Chattem Chemicals, Inc.

Rowett Research Services (RRS) will supply the technology, thanks to its research parent, the Rowett Institute. It will even throw in marketing services and project management. All RRS needs are companies interested in commercializing new ideas and products. Its primary focuses are nutrition issues and outpatient health care studies, such as antimicrobial agents and antioxidants. Founded in 1988, RRS works with public and private partners in the pharmaceutical, biotechnology, food, and agricultural industries to bring the research underway at the Rowett Institute to the marketplace.

Dow Pharmaceutical Sciences company researches and develops topical dermatological pharmaceutical and biotech products for external clients. It works to formulate the gel, ointment, or cream that will carry a client's drug, assesses its effectiveness, manufactures and packages product candidates for clinical trials, and provides regulatory affairs consulting. It provides contract research services through its Solano Clinical Research division in the US and its Bioskin subsidiary in Europe. Dow Pharmaceutical Sciences also develops dermatology products on a proprietary basis. The company is owned by Valeant Pharmaceuticals.

Amgen Inc. company was founded in 1980 and is based in Thousand Oaks, California. Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN that stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company has a joint venture with Kirin Holdings Company, Limited to manufacture and market darbepoetin alfa; a co-promotion agreement with Wyeth for marketing and selling of ENBREL; and Johnson & Johnson to commercialize recombinant human erythropoietin as a human therapeutic. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe, and Canada.

Dey, L.P. company, a subsidiary of generic drugmaker Mylan, makes prescription drugs for the treatment of allergies and respiratory diseases. Dey markets EpiPen autoinjectors, used by patients to self-administer epinephrine for severe allergic reactions. Its premeasured unit-dose inhalation products include treatments for asthma and chronic obstructive pulmonary disease (COPD). These treatments, called bronchodialators, are used in air-driven breathing devices called nebulizers and include branded DuoNeb and Perforomist products. It also offers several non-branded generic nebulizer treatments. A direct sales force markets Dey's products to doctors, pharmacies, and wholesalers.

Orion shines brightly over Scandinavia. At the heart of the health care group is Orion Pharma, one of Finland's largest drug makers. Orion Pharma manufactures prescription, generic, and OTC pharmaceuticals, as well as veterinary medicines. Its Fermion subsidiary manufactures active pharmaceutical ingredients (API) for use by Orion and other drug makers. Orion company's research is focused on developing treatments for central nervous system, cardiovascular, and urological disorders, as well as cancer. Orion Diagnostica develops and manufactures diagnostic tests to be used on site in physicians' offices.

CombiMatrix Corporation company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, defense, and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology.CombiMatrix Corporation's products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix Corporation also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, the company develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. It sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia.

EquiTech Corporation company focuses on improving the effectiveness of commonly used drugs primarily by enhancing the absorbtion of the drugs. Its ZAG-1701 is a fast-acting ibuprofen pill designed to treat pain, including dental, fractural, and post-operative incision pain as well as migraines and other headaches. EquiTech has a strategic partnership with fellow Canadian company Ethypharm Inc., developer and manufacturer of drug delivery systems. EquiTech company was founded by chief scientific officer Fakhreddin Jamali after he discovered that absorption of pain medication is slowed when a patient is in pain.

Protalix BioTherapeutics, Inc. ompany was founded in 1993 and is based in Carmiel, Israel. Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in the United States. Its lead product candidate includes prGCD, a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme for the treatment of Gaucher disease, which is in Phase III clinical trial. The company also develops PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; a proprietary plant cell-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an organophosphate-based pesticide treatment program. Protalix BioTherapeutics, Inc. has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the company's ProCellEx protein expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher disease, as well as has a licensing agreement with Icon Genetics AG to license Icon's amplification technology for utilization in the expression of its products.

Odyssey Thera researches new treatments for cancer and rheumatoid arthritis using its protein-fragment complementation assays (PCAs) to observe the action of small molecules and proteins. Essentially, it works to improve the speed and predictability of the drugs it studies. It technologies expedite the discovery and uses of drugs as well as track the development of new drug therapies. Odyssey partners with large drug makers such as Roche and Pfizer to profile selected compounds across its panel of assays to identify potential lead drug candidates. In 2005 it partnered with Bristol-Myers Squibb to analyze its compounds.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.